Gene therapy for lysosomal storage disorders

Bibliography

• DE DUVE C, PRESSMAN B,GIANETTO R et al.: Tissue fractionation studies: intracellular distribution patterns of enzymes in rat-liver tissue. Biochem. .1. (1955) 60:604-617.
   Google Scholar
• DE DUVE C, WATTIAUX R: Functions of lysosomes. Ann. Rev Physiol (1966) 28:435–492.
   PubMed Web of Science ®Google Scholar
• DE DUVE C: Lysosomes revisited. EuL Biochem. (1983) 137:391–397.
   PubMedGoogle Scholar
• LEROY J, DEMARS R: Mutant enzymatic and cytological phenotypes in cultured human fibroblasts. Science (1967) 157:804–806.
   PubMedGoogle Scholar
• HICKMAN S, NEUFELD E: A hypothesis for I-cell disease: defective hydrolases that do not enter lysosomes. Biochem. Biophys. Res. Comm. (1972) 49:992–999.
   PubMed Web of Science ®Google Scholar
• SLY W, LAG WINSKA E,SCHLESINGER S: Enveloped virus acquires membrane defect when passaged in fibroblasts from I-cell disease patients. Proc. NatL Acad. Sci. USA (1976) 73:2443–2447.
   PubMed Web of Science ®Google Scholar
• REITMAN M, VARKI A, KORNFELD S:Fibroblasts from patients with I-cell disease and pseudo-Hruler polydystrophy are deficient in uridine 5'-diphosphate-N-acetylglucosamine: glycoprotein N-acetylglucosaminylphosphotransferase activity.' Gin. Invest. (1981) 67:1574–1579.
   PubMed Web of Science ®Google Scholar
• WILLINGHAM M, PASTAN I,SAHAGIAN G et al: Morphologic study of the internalization of a lysosomal enzyme by the mannose 6-phosphate receptor in cultured Chinese hamster ovary cells. Proc. NatL Acad. Sci. USA (1981) 78:6967–6971.
   PubMed Web of Science ®Google Scholar
• MA Z, GRUBB J, SLY W: Cloning, sequencing, and functional characterization of the murine 46-kDa mannose 6-phosphate receptor. J. Bio/. Chem. (1991) 266:10589–10595.
   PubMed Web of Science ®Google Scholar
• OSHIMA A, NOLAN C, KYLE J et al: The human cation-independent mannose 6-phosphate receptor. J. Biol. Chem. (1988) 263:2553–2562.
   PubMed Web of Science ®Google Scholar
• LOBEL P, DAHMS N, KORNFELD S: Cloning and sequence analysis of the cation-independent mannose 6-phosphate receptor. Biol. Chem. (1988) 263:2563–2570.
   Web of Science ®Google Scholar
• WAHEED A, HASILIK A,VON FIGURA K: Processing of the phosphorylated recognition marker in lysosomal enzymes. J. Biol. Chem. (1981) 256:5717–5721.
   PubMed Web of Science ®Google Scholar
• DAHMS N, LOBEL P, KORNFELD S: Mannose 6-phosphate receptors and lysosomal enzyme targeting. J. Biol. Chem. (1989) 264:12115–12118.
   PubMed Web of Science ®Google Scholar
• SCHWEIZER A, KORNFELD S, ROHRER J: Proper sorting of the cation-dependent mannose 6-phosphate receptor in endosomes depends on a pair of aromatic amino acids in its cytoplasmic tail. Proc. Natl. Acad. Sci. USA (1997) 94:14471–14476.
   PubMed Web of Science ®Google Scholar
• SAHAGIAN G, NEUFELD E: Biosynthesis and turnover of the mannose 6-phosphate receptor in cultured Chinese hamster ovary cells." Biol. Chem. (1983) 258:7121–7128.
   PubMed Web of Science ®Google Scholar
• WINCHESTER B, VELLODI A, YOUNG E: The molecular basis of lysosomal storage diseases and their treatment. Biochem. Soc. Trans (2000) 28:150–154.
   PubMed Web of Science ®Google Scholar
• HERS H: Alpha-glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease). Biochem. .1. (1963) 86:11-16.
   Google Scholar
• SCRIVER CR, BEAUDET A, SLY W et al.: The Metabolic and Molecular Bash of Inherited Disease. 7 ed., Scriver CR, Beaudet A, Sly W (Eds), McGraw-Hill, New York (1995).
   Google Scholar
• MCKUSICK VA: Mendelian inheritance in man. lied, Johns Hopkins University Press, Baltimore (1995).
   Google Scholar
• HANNUN Y, BELL R: Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science (1987) 235:670–674.
   PubMed Web of Science ®Google Scholar
• TURNER BM, TURNER VS,HIRSCHHORN K: Metabolic correction of fucosidosis fibroblasts by human alpha-L-fucosidase. J. Cell Physiol. (1979) 98:225–235.
   PubMed Web of Science ®Google Scholar
• DAWSON G, MATALON R, LI YT: Enzyme replacement in Fabry disease: treatment of cultured skin fibroblasts with a purified alpha-galactosidase from ficin. Birth Defects Orig. Artie. Ser. (1973) 9:97–101.
   PubMedGoogle Scholar
• BRADY RO, MURRAY GJ,BARTON NW: Modifying exogenous glucocerebroside for effective replacement therapy in Gaucher disease.' Inher: Metab. Dis. (1994) 17:510–519.
   PubMed Web of Science ®Google Scholar
• ENG CM, GUFFON N, WILCOX WR et al.: Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl. I Med. (2001) 345:9–16.
   PubMed Web of Science ®Google Scholar
• •This study describes the successful treatment of Fabry patients by ERT with recombinant a-galactosidase A. See aslo [32].
   Google Scholar
• ZIRZOW GC, SANCHEZ OA,MURRAY GJ et al.: Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain. Neurochem. Res. (1999) 24:301–305.
   Google Scholar
• HOOGERBRUGGE PM, VALERIO D: Bone marrow transplantation and gene therapy for lysosomal storage diseases. Bone Marrow Transplant. (1998) 21\(Suppl. 2):534–536.
   Google Scholar
• HUIJING F, WALTUCK BL,WHELAN WJ: a-Glucosidaseadministration: experiences in two patients with glycogen storage disease compared with animal experiments. In: Enzyme Therapy M Genetic Diseases, Krivit W (Ed) Williams and Wilkins, Baltimore (1973):191–194.
   Google Scholar
• BEUTLER E, DALE GL, GUINTO E et al.: Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation. Proc. NatL Acad. ScL USA (1977) 74:4620–4623.
   PubMed Web of Science ®Google Scholar
• DESNICK RJ, DAWSON G, DESNICK SJet al.: Diagnosis of glycosphingolipidoses byurinary-sediment analysis. N Eng]. I Med. (1971) 284:739–744.
   Google Scholar
• MASEK BJ, SIMS KB, BOVE CM et al.: Quality of life assessment in adults with Type 1 Gaucher disease. Qual. Life Res. (1999) 8:263–268.
   PubMed Web of Science ®Google Scholar
• BRADY RO: Gaucher's disease: past, present and future. Baillieres Clin. Haeinatoi (1997) 10:621–634.
   PubMedGoogle Scholar
• SCHIFFMANN R, KOPP JB,AUSTIN HA 3RD et al.: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA (2001) 285:2743–2749.
   Google Scholar
• THURBERG BL, RENNKE H,COLVIN RB et al.: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. (2002) 62:1933–1946.
   Google Scholar
• DUNDER U, KAARTINEN V,VALTONEN P et al.: Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB (2000) 14:361–367.
   Google Scholar
• IOANNOU YA, ZEIDNER KM, GORDON RE et al.: Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am.j Hum. Genet. (2001) 68:14–25.
   PubMed Web of Science ®Google Scholar
• KAKKIS ED, SCHUCHMAN E, HEX et al.: Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol. Genet. Metab. (2001) 72:199–208.
   PubMed Web of Science ®Google Scholar
• KAKKIS ED, MCENTEE MESCHMIDTCHEN A et al.: Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem. Mol. Med. (1996) 58:156–167.
   Google Scholar
• CRAWLEY AC, BROOKS DA,MULLER VJ et al.: Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. Clin. Invest. (1996) 97:1864–1873.
   Google Scholar
• CRAWLEY AC, NIEDZIELSKI KH, ISAAC EL et al.: Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis Type VI. I. Clin. Invest. (1997) 99:651–662.
   PubMed Web of Science ®Google Scholar
• SANDS MS, VOGLER C, KYLE JVV etal.: Enzyme replacement therapy for murine mucopolysaccharidosis Type VII.' Clin. Invest. (1994) 93:2324–2331.
   Google Scholar
• BYERS S, CRAWLEY AC, BRUMFIELD LK et al.: Enzymereplacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency. Pediam Res. (2000) 47:743–749.
   PubMed Web of Science ®Google Scholar
• YU WH, ZHAO KW, RYAZANTSEV S etal.: Short-term enzyme replacement in the murine model of Sanfilippo syndrome type B. Mol. Genet. Metab. (2000) 71:573–580.
   Google Scholar
• DOWNS-KELLY E, JONES MZ,ALROY J et al.: Caprinemucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy. J. Mol. Neurosci (2000) 15:251–262.
   Google Scholar
• ETO Y, OHASHI T: Novel treatment for neuronopathic lysosomal storage diseases-cell therapy/gene therapy. Curt: Mol. Med. (2002) 2:83–89.
   PubMedGoogle Scholar
• SCHIFFMANN R, BRADY RO: New prospects for the treatment of lysosomal storage diseases. Drugs (2002) 62:733–742.
   PubMed Web of Science ®Google Scholar
• DEGLON N, AEBISCHER P:Lentiviruses as vectors for CNS diseases. Carr: Top. Microbiol. Immunol. (2002) 261:191–209.
   PubMed Web of Science ®Google Scholar
• CABRERA-SALAZAR MA, NOVELLI E, BARRANGER JA: Gene therapy for the lysosomal storage disorders. Curt: Opin. Mol. Their (2002) 4:349–358.
   PubMed Web of Science ®Google Scholar
• TABIN CJ, HOFFMAN JW, GOFF SP etal.: Adaptation of a retrovirus as a eucaryotic vector transmitting the herpes simplex thymidine kinase gene. Mol. Cell Biol. (1982) 2:426–436.
   Google Scholar
• SHIMOTOHNO K, TEMIN HM: Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell (1981) 26:67–77.
   PubMed Web of Science ®Google Scholar
• MARSHALL E: Gene therapy. What to do when clear success comes with an unclear risk? Science (2002) 298:510–511.
   Google Scholar
• MARSHALL E: Clinical research. Gene therapy a suspect in leukemia-like disease. Science (2002) 298:34–35.
   Google Scholar
• KIM VN, MITROPHANOUS K, KINGSMAN SM etal.: Minimal requirement for a lentivirus vector based on human immunodefiency virus Type 1. Virol. (1998) 72:811–816.
   Google Scholar
• JACOBY DR, FRAEFEL C,BREAKEFIELD XO: Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes [editorial]. Gene flier. (1997) 4:1281–1283.
   Web of Science ®Google Scholar
• MATZNER U, HABETHA M, GIESELMANN V: Retrovirally expressed human arylsulfatase A corrects the metabolicdefect of arylsulfatase A-deficient mouse cells. Gene flier (2000) 7:805–812.
   Web of Science ®Google Scholar
• MATZNER U, HARTMANN D, LULLMANN-RAUCH R et al.: Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations. Gene Mei: (2002) 9:53–63.
   Google Scholar
• XU L, MANGO RL, SANDS MS etal.: Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol. flier. (2002) 6:745–758.
   Google Scholar
• LEIMIG T, MANN L, MARTIN MDEL P etal.: Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells. Blood (2002) 99:3169–3178.
   Google Scholar
• XU L, HASKINS ME, MELNICZEK JR etal.: Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs. Mol. flier (2002) 5:141–153.
   Google Scholar
• PONDER KP, MELNICZEK JR, XU L etal.: Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc. Natl. Acad. Sci. USA (2002) 99:13102–13107.
   PubMed Web of Science ®Google Scholar
• LUDDI A, VOLTERRANI M, STRAZZA M etal.: Retrovirus-mediated gene transfer and galactocerebrosidase uptake into twitcher glial cells results in appropriate localization and phenotype correction. Neurobiol. Dis. (2001) 8:600–610.
   Google Scholar
• TOIETTA G, SEVERINI GM, TRAVERSARI C et al.: Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts M vitro. Hum. Gene flier (2001) 12:2007–2016.
   Google Scholar
• BAXTER MA, WYNN RE DEAKIN JA etal.: Retrovirally mediated correction of bone marrow-derived mesenchymal stem cells from patients with mucopolysaccharidosis Type I. Blood (2002) 99:1857–1859.
   Google Scholar
• CONSIGLIO A, QUATTRINI A, MARTINO S et al.: In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. (2001) 7:310–316.
   PubMed Web of Science ®Google Scholar
• •Demonstration of successful metachromatic leukodystrophy disease reversal through an in vivo brain injection of a lentiviral vector.
   Google Scholar
• BOSCH A, PERRET E, DESMARIS N et al.: Reversal of pathology in the entire brain of mucopolysaccharidosis Type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. (2000) 11:1139–1150.
   PubMed Web of Science ®Google Scholar
• BUCHET D, SERGUERA C,ZENNOU V et al.: Long-term expression of beta-glucuronidase by genetically modified human neural progenitor cells grafted into the mouse central nervous system. Mol. Cell Neurosci. (2002) 19:389–401.
   Google Scholar
• DI NATALE P, DI DOMENICO C, VILLANI GR et al.: In vitro gene therapy of mucopolysaccharidosis Type I by lentiviral vectors. Eur.j Biochem. (2002) 269:2764–2771.
   PubMedGoogle Scholar
• VILLANI GR, FOLLENZI A,VANAC ORE B et al.: Correction of mucopolysaccharidosis Type Mb fibroblasts by lentiviral vector-mediated gene transfer. Biochem. (2002) 364:747–753.
   Google Scholar
• ALI M, LEMOINE NR, RING CJA: The use of DNA viruses as vectors for gene therapy. Gene Ther. (1994) 1:367–384.
   PubMed Web of Science ®Google Scholar
• ORAL HB, LARKIN DF, FEHERVARI Z et al.: Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea. Gene Tiler. (1997) 4:639–647.
   Web of Science ®Google Scholar
• MITCHELL P: Vector problems still thwartgene-therapy promise. Lancet (1998) 351:346.
   PubMed Web of Science ®Google Scholar
• FINE LG: Gene transfer into the kidney: promise for unraveling disease mechanisms, limitations for human gene therapy. Kidney Int. (1996) 49:612–619.
   PubMed Web of Science ®Google Scholar
• SHEN JS, WATABE K, OHASHI T et al.: Intraventricular administration of recombinant adenovirus to neonatal twitcher mouse leads to clinicopathological improvements. Gene The]: (2001) 8:1081–1087.
   PubMed Web of Science ®Google Scholar
• KAMATA Y, TANABE A, KANAJI A et al:Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII. Gene Ther (2003) 10:406–414.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates that systemic injection of adenovirus in neonatal mice can reach the CNS, suggesting that, in the mouse, the blood-brain barrier is not fully formed at this age.
   Google Scholar
• DING E, HUH, HODGES BL et al.:Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol. The]: (2002) 5:436–446.
   PubMed Web of Science ®Google Scholar
• •A detailed study on the levels of lysosomal enzyme expression necessary to achieve a therapeutically beneficial bystander effect.
   Google Scholar
• AMALFITANO A, MCVIE-WYLIE AJ, HU H et al.: Systemic correction of the muscle disorder glycogen storage disease Type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc. Nati Acad. Sci. USA (1999) 96:8861–8866.
   PubMed Web of Science ®Google Scholar
• DU H, HEUR M, WITTE DP et al.: Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice. Hum. Gene Tiler. (2002) 13:1361–1372.
   PubMed Web of Science ®Google Scholar
• ZIEGLER RJ, YEW NS, LI C et al.: Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum. Gene Ther. (1999) 10:1667–1682.
   PubMed Web of Science ®Google Scholar
• MARSHALL J, MCEACHERN KA, KYROS JA et al.: Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model. Mol. The]: (2002) 6:179–189.
   PubMed Web of Science ®Google Scholar
• XIAO X, LI J, MCCOWN TJ et al: Gene transfer by adeno-associated virus vectors into the central nervous system. Exp. Nemo]. (1997) 144:113–124.
   PubMed Web of Science ®Google Scholar
• XIAO X, LI J, SAMULSKI RJ: Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. Viroi (1996) 70:8098–8108.
   PubMed Web of Science ®Google Scholar
• SFERRA TJ, QU G, MCNEELY D et al:Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis Type VII mouse. Hum. Gene The,: (2000) 11:507–519.
   Google Scholar
• ELLIGER SS, ELLIGER CA, AGUILAR CP et al.: Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene The,: (1999) 6:1175–1178.
   Web of Science ®Google Scholar
• FRISELLA WA, O& CONNOR LH, VOGLER CA et al: Intracranial injection of recombinant adeno-associated virusimproves cognitive function in a murine model of mucopolysaccharidosis Type VII. Mol. Ther. (2001) 3:351–358.
   PubMed Web of Science ®Google Scholar
• DALY TM, VOGLER C, LEVY B et al: Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Nati Acad. St". USA (1999) 96:2296–2300.
   PubMed Web of Science ®Google Scholar
• DALY TM, OHLEMILLER KK, ROBERTS MS et al.: Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther (2001) 8:1291–1298.
   PubMed Web of Science ®Google Scholar
• ELLIGER SS, ELLIGER CA, LANG C et al.: Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis Type VII mice. Mol. Ther. (2002) 5:617–626.
   PubMed Web of Science ®Google Scholar
• HENNIG AK, LEVY B, OGILVIE JM et al.: Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. Neurosci. (2003) 23:3302–3307.
   PubMed Web of Science ®Google Scholar
• ••A new injection route for treating theCNS. In this study, the authors demonstrate that intravitreal injection of AAV results in the reduction of lysosomal storage in non-visual adjacent areas, suggesting that this approach could be potentially beneficial for delivering lysosomal enzymes to the CNS.
   Google Scholar
• JUNG SC, HAN IP, LIMAYE A et al.: Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc. Nati Acad. St". USA (2001) 98:2676–2681.
   Google Scholar
• TAKAHASHI H, HIRAI Y, MIGITA M et al.: Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc. Natl. Acad. Sci. USA (2002) 99:13777–13782.
   PubMed Web of Science ®Google Scholar
• PARK J, MURRAY GJ, LIMAYE A et al.: Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc. Natl. Acad. Sci. USA (2003) 100:3450–3454.
   PubMed Web of Science ®Google Scholar
• FRAITES TJ JR, SCHLEISSING MR, SHANELY RA et al.: Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol. Ther. (2002) 5:571–578.
   PubMed Web of Science ®Google Scholar
• LIN CY, HO CH, HSIEH YH et al: Adeno-associated virus-mediated transfer of human acid maltase gene results in a Expert Op/n. Biol. Ther. (2003) 3(5)transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency. Gene Ther: (2002) 9:554–563.
   Google Scholar
• FU H, SAMULSKI RJ, MCCOWN TJ et al.: Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Ma Ther. (2002) 5:42–49.
   PubMed Web of Science ®Google Scholar
• ZABNER J, FASBENDER AJ, MONIGER T et al.: Cellular and molecular barriers to gene transfer by a cationic lipid. Biol Chem. (1995) 270:18997–19007.
   Web of Science ®Google Scholar
• MAHATO RI, TAKAKURA Y,HASHIDA M: Nonviral vectors for in vivo gene delivery: physiochemical and pharmacokinetic considerations. Crit. Rev Ther. Drug Carrier Syst. (1997) 14:133–172.
   PubMed Web of Science ®Google Scholar
• GALBRAITH GM, GALBRAITH RM: Metabolic and cytoskeletal modulation of transferrin receptor mobility in mitogen-activated human lymphocytes. Clin. Exp. Immunol. (1980) 42:285–293.
   PubMed Web of Science ®Google Scholar
• GODBEY W, WU K, HIRASAKI G etal.: Improved packing of poly(ethylenimine)/ DNA complexes increases transfection efficiency. Gene The]: (1999) 6:1380–1388.
   Google Scholar
• OGRIS M, BRUNNER S, SCHULLER Set a/.: PEGylated DNA/transferrin-PEI complexees: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene The]: (1999) 6:595–605.
   Google Scholar
• WAGNER E, COTTEN M, MECHTLER K et al.: DNA-binding transferrin conjugates as functional gene-delivery agents: Synthesis by linkage of polylysine or ethidium homodimer to the transferrin carbohydrate moiety. Bioconjug. Chem. (1991) 2:226–231.
   PubMed Web of Science ®Google Scholar
• DIEBOLD SS, KURSA M, WAGNER E etal.: Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. Biol. Chem (1999) 274:19087–19094.
   Google Scholar
• KIRCHEIS R, KICHLER A, WALLNER G et al.: Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. (1997) 4:409–418.
   PubMed Web of Science ®Google Scholar
• ESTRUCH EJ, HART SL, KINNON C etal.: Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases. J. Gene Med. (2001) 3:488–497.
   Google Scholar
• TOMANIN R, FRISO A, ALBA S et al: Non-viral transfer approaches for the genetherapy of mucopolysaccharidosis Type II (Hunter syndrome). Acta Paediatr. Sapp]. (2002) 91:100–104.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI A, KATSUYAMA K, SUZUKI K etal.: Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease. I Ma Med. (2003) 81:185–193.
   Google Scholar
• MARSHALL E: Improving gene therapy's tool kit. Science (2000) 288:953.
   PubMedGoogle Scholar
• http://217.215.32.12/trials/ The Journal of Gene Medicine Clinical Trial site.
   Google Scholar